Journal ArticleDOI
Gonadal dysfunction in patients receiving chemotherapy for cancer.
TLDR
The clinical syndromes of chemotherapy-related gonadal toxicity are reviewed and how particular drug classes, doses, or combinations correlate with the degree of gonadal injury and with the potential for recovery of function are discussed.Abstract:
Since the introduction of antineoplastic chemotherapy, lasting clinical remissions have been obtained for many patients with acute lymphoblastic leukemia, Hodgkin's disease, gestational trophoblastic tumors, and other malignancies. With this therapeutic success there have been concerns about persistent or delayed toxicities of cancer chemotherapy that may become clinically significant for long-term survivors. Gonadal toxicity and infertility occur in many men, women, and children treated with antineoplastic drugs. In this paper we review the clinical syndromes of chemotherapy-related gonadal toxicity and discuss how particular drug classes, doses, or combinations correlate with the degree of gonadal injury and with the potential for recovery of function. Further, we examine how drug effects on germ cell production and endocrine function vary with the age of the patient at the time of treatment. Finally, we comment on the need for long-term prospective studies of fertility, teratogenesis, and mutagenesis in patients receiving cancer chemotherapy.read more
Citations
More filters
Journal ArticleDOI
Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer.
TL;DR: Ovarian damage is the most significant long-term sequela of adjuvant chemotherapy in premenopausal breast cancer survivors and a common definition of the following important terms is suggested: menopausal status, CRA (early and late), temporary CRA, and oligomenorrhea in the setting of adjUvant treatment.
Journal ArticleDOI
Risk for Sustained Amenorrhea in Patients with Systemic Lupus Erythematosus Receiving Intermittent Pulse Cyclophosphamide Therapy
Dimitrios T. Boumpas,Howard A. Austin,Ellen M. Vaughan,Cheryl Yarboro,John H. Klippel,James E. Balow +5 more
TL;DR: The data suggest that intermittent pulse cyclophosphamide therapy is associated with secondary amenorrhea and that duration of therapy and age are independent risk factors, and the toxicity rates provided by this study should be useful to physicians and patients before they decide whether to use pulse cyclophile therapy.
Journal ArticleDOI
American Gastroenterological Association Institute Technical Review on Corticosteroids, Immunomodulators, and Infliximab in Inflammatory Bowel Disease
TL;DR: This work was funded in part by the National Institutes of Health and the generosity of the generous donors of the University of Pennsylvania and the City of Philadelphia.
Journal ArticleDOI
Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD.
TL;DR: Findings confirm that the two alkylating agents, mechlorethamine and procarbazine, included in the MOPP regimen cause sterility in most patients while the drugs included in ABVD are not associated with permanent gonadal dysfunction.
Journal ArticleDOI
ABVD Plus Subtotal Nodal Versus Involved-Field Radiotherapy in Early-Stage Hodgkin's Disease: Long-Term Results
Gianni Bonadonna,Valeria Bonfante,Simonetta Viviani,Anna Di Russo,F. Villani,Pinuccia Valagussa +5 more
TL;DR: Present long-term findings suggest that, after four cycles of ABVD, I FRT can achieve a worthwhile outcome, and ABVD followed by IFRT can be considered an effective and safe modality in early Hodgkin's disease with both favorable and unfavorable presentation.
References
More filters
Journal ArticleDOI
Cis-Diamminedichloroplatinum, Vinblastine, and Bleomycin Combination Chemotherapy in Disseminated Testicular Cancer
TL;DR: In this paper, a three-drug combination consisting of cis-diamminedichloroplatinum, vinblastine, and bleomycin was used to treat 50 patients with disseminated testicular cancer.
Milestone in Urology Cis-Diamminedichloroplatinum, Vinblastine, and Bleomycin Combination Chemotherapy in Disseminated Testicular Cancer
TL;DR: Fifty patients with disseminated testicular cancer were treated with a three-drug combination consisting of cis-diamminedichloroplatinum, vinblastine, and bleomycin, producing an overall 85% disease-free status.
Journal ArticleDOI
Sterility and testicular atrophy related to cyclophosphamide therapy.
TL;DR: All samples of seminal fluid from thirty-one adult male patients who had received cyclophosphamide showed low sperm-counts or azoospermia, and preliminary studies suggest that cycloph phosphamide may also cause ovarian damage.
Journal ArticleDOI
Cyclophosphamide-induced ovarian failure.
TL;DR: One patient judged clinically and biochemically to have ovarian failure regained normal ovarian function 10 months after cessation of cyclophosphamide therapy.
Journal ArticleDOI
Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer
Hiroki Koyama,Wada T,Yukio Nishizawa,Takeshi Iwanaga,Yukitoshi Aoki,Toshio Terasawa,Goro Kosaki,Toshihide Yamamoto,Akira Wada +8 more
TL;DR: It is found that CY induced primary ovarian failure in patients with breast cancer receiving prolonged daily administration of this agent after radical surgery, and no ovarian follicle was histologically found in three amenorrheic patients who underwent therapeutic oopho‐rectomy after CY therapy.